Prakruti R Pali increased his stake in Asston Pharmaceuticals Limited to 5.33% following an open market acquisition of 2,40,000 equity shares. The transaction took place on August 27, 2026.

The acquisition was disclosed under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Pali, who is not part of the promoter group, purchased the fully paid-up equity shares through the open market mechanism.

Holding Details

Prior to this transaction, Pali held 2,14,000 shares, representing a 2.51% stake in the company. The new purchase added 2.82% to his existing holding. Following the acquisition, his total holding stands at 4,54,000 shares.

The shares are listed on the Bombay Stock Exchange SME Platform. There were no warrants, convertible securities, or voting rights other than by shares involved in the transaction. Additionally, none of the shares held by Pali are encumbered by pledge, lien, or non-disposal undertakings.

Asston Pharmaceuticals has scheduled a board meeting for September 4, 2026, to approve remuneration increases for its managing director and whole-time director. The session will also finalize the appointment of the company’s statutory auditor.

The board intends to review and approve the appointment of M/s Panchal S K & Associates as the statutory auditor. The firm holds Peer Review Certificate No. 018089 and Firm Registration No. 145989W.

Key Agenda Items

The meeting agenda focuses on governance adjustments and compensation reviews for senior leadership. Key decisions include:

• Increase in remuneration for Ashish Narayan Sakalkar, Managing Director.
• Increase in remuneration for Saili Jayaram More, Whole Time Director and CEO.
• Increase in remuneration for Sachin Chandrakant Badakh, Non-Executive Director.

The board will also ascertain the directors retiring by rotation and approve the date and draft notice for the company’s seventh Annual General Meeting.

Regulatory Compliance

The intimation was issued pursuant to Regulation 29(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Rishi Upadhaya, Company Secretary & Compliance Officer, signed the disclosure on August 27, 2026.